Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 6 years or older at the time of signing consent forms. Children aged 12 months to under 6 years may also be eligible depending on which part of the trial is currently open (confirm with trial site).
• People (or their parents or legal guardians) who are able and willing to sign a consent form agreeing to take part. For younger children, age-appropriate agreement will also be sought where guidelines require it.
• People who are well enough to carry out at least 60% of normal daily activities, as measured by a standard medical scoring scale appropriate for their age.
• People diagnosed with a Wilms tumor or nephroblastoma (a type of kidney cancer) who meet at least one of these conditions: they are in their second or later relapse; they have a high-risk tumour type and are in their first relapse or the tumour has not responded to treatment; or they have relapsed after receiving a more intensive treatment regimen than the standard first-line options (confirm with trial site for specific regimens).
• People diagnosed with any type of rhabdoid tumour — including those in the brain, kidney, soft tissue, liver, or ovary — who have already received at least one course of treatment that did not work.
• People with a type of nerve sheath tumour called a malignant peripheral nerve sheath tumour (MPNST) that has grown, come back, cannot be surgically removed, or has spread, and who have already received at least one course of treatment that did not work.
• People with a solid tumour (not a blood cancer or lymphoma) that is not covered by the groups above, but where there is specific scientific evidence suggesting their tumour may respond to the study drug selinexor — this requires approval from the lead study doctor and supporting documentation (confirm with trial site).
• People with a solid tumour that has a specific type of genetic change involving a gene called BCOR — for example certain fusions or duplications — as confirmed by genetic testing. Other BCOR changes may qualify with lead study doctor approval (confirm with trial site).
• People whose cancer can be measured on scans (for the main phase of the trial). People in the early drug-level testing part of the trial may have disease that is either measurable or detectable.
• People who have fully recovered from the side effects of any previous cancer treatment, and who have waited the required amount of time since their last treatment — ranging from 7 days (for some non-intensive drugs) up to 84 days (for a bone marrow transplant from a donor), depending on the treatment type.
• People with adequate liver function, as shown by blood tests taken within the two weeks before starting the study drug.
• People with adequate kidney function, confirmed by kidney tests taken within the two weeks before starting the study drug, showing the kidneys are filtering at an acceptable level.
• People with adequate blood cell counts, confirmed by blood tests taken within the two weeks before starting the study drug, and who have not received blood platelet transfusions or certain blood-boosting injections in the 7 days before those tests.

Who may not be able to join:

• People who have previously been treated with selinexor or any other drug in the same class (called XPO1 inhibitors).
• People who currently have an infection that is not under control. People on preventative antibiotics or with a recently controlled infection may still be considered (confirm with trial site).
• People who have previously received a solid organ transplant (such as a kidney or liver transplant).
• People who have had a bone marrow transplant using cells from a donor and are currently receiving active treatment for graft-versus-host disease (a complication of that transplant).
• People whose medical, mental health, or personal circumstances mean, in the treating doctor's judgement, they may not be able to follow the study's safety monitoring or care requirements.
• People who are pregnant or breastfeeding. Girls who have started their periods will need to take a pregnancy test before joining.
• People of reproductive age who are not willing to use two effective methods of contraception (such as barrier methods like condoms) for the duration of the study. Abstinence is considered an acceptable method.

Important: Always verify eligibility with the trial site directly before applying.